Cargando…
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
PURPOSE: The prognosis for patients diagnosed with glioblastoma multiforme (GBM) remains dismal, with current treatment prolonging survival only modestly. As such, there remains a strong need for novel therapeutic strategies. The janus kinase (JAK)2/signal transducer and activator of transcription (...
Autores principales: | Jensen, Katharine Victoria, Cseh, Orsolya, Aman, Ahmed, Weiss, Samuel, Luchman, Hema Artee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734728/ https://www.ncbi.nlm.nih.gov/pubmed/29253028 http://dx.doi.org/10.1371/journal.pone.0189670 |
Ejemplares similares
-
EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
por: Jensen, Katharine V, et al.
Publicado: (2020) -
SLUG Directs the Precursor State of Human Brain Tumor Stem Cells
por: Chesnelong, Charles, et al.
Publicado: (2019) -
Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics
por: Bahia, Ravinder K., et al.
Publicado: (2023) -
The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022) -
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)